Novartis Hyping Potential Multiple Myeloma Treatment

Pharmaceutical giant Novartis is reporting positive early results of a phase III trial involving the company's investigational compound known as LBH589, a pan-deacetylase inhibitor indicated for the treatment of heavily pretreated patients with multiple myeloma, a cancer of the blood's plasma cells.

Specifically, they are reporting that LBH589 in combination with the anti-cancer drug bortezomib and the corticosteroid dexamethasone out-performed bortezomib, dexamethasone, and a placebo in a trial, the primary end point of which was progression-free survival (PFS). Patients were said to have relapsed or relapsed and refractory multiple myeloma.

In a statement, Alessandro Riva, Global Head, Oncology Development and Medical Affairs, Novartis Oncology said:

Results from this study show improved outcomes for these multiple myeloma patients who otherwise have few options to treat this incurable disease. Given its mechanism of action, LBH589 has the potential to be an important treatment option for multiple myeloma.

The company will present complete data from this trial, called the PANORAMA-1 (PANobinostat ORAl in Multiple MyelomA) trial, at an upcoming medical conference. Novartis is one of at least three pharmaceutical companies currently working on a multiple myeloma treatment.

Currently there is no cure for multiple myeloma. Estimates put the number of new cases in the United States at around 22,000, and the number of deaths from the disease around 10,000.

It is important to note that progression-free survival is a dubious end-point, since it has not shown to extend survival times in cancer patients.

Source: Novartis

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap